STING Promoter Methylation Detection for Cancer Immunotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively monitor and enhance STING promoter methylation status in tumor cells, which is crucial for determining treatment responses in cancers, particularly for immunotherapy, as STING signaling is often disrupted in various cancers leading to poor treatment outcomes.
Innovation Solution
A method involving the determination of methylation status of the STING promoter in tumor cells using specific CpG sites, followed by administration of demethylating agents like azacitidine or decitabine to restore STING expression and function, and subsequent immunotherapy for improved treatment outcomes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If STING promoter methylation status is not monitored, then treatment decisions cannot be personalized, but monitoring methods are currently ineffective or unavailable
Solution Approach 1:
The patent uses methylation-sensitive restriction enzymes as intermediaries to detect STING promoter methylation status. These enzymes selectively cut methylated DNA at specific recognition sites, allowing indirect detection of methylation through analysis of DNA fragment patterns, thereby solving the difficulty of directly measuring methylation status in tumor cells
Solution Approach 2:
The patent replaces complex direct methylation detection mechanisms with a simplified enzymatic restriction system. By using methylation-sensitive restriction enzymes that recognize specific DNA sequences only when methylated, the method substitutes complex biochemical detection with a more straightforward enzymatic reaction and fragment analysis approach
2Reliability
If STING signaling is disrupted through methylation, then cancer progression is facilitated, but restoring STING function through demethylation is challenging
Solution Approach 1:
The patent performs preliminary methylation status detection before initiating treatment. By assessing the methylation state of the STING promoter in tumor cells prior to therapy, the method enables personalized treatment selection and timing of demethylation agents, ensuring intervention occurs when most likely to restore STING function effectively
Solution Approach 2:
The patent utilizes demethylating agents that chemically modify the methylation state of CpG sites in the STING promoter. These agents alter the chemical parameters of DNA methylation, converting methylated cytosines to unmethylated states, thereby restoring STING promoter activity and signaling function in a controlled manner
3Productivity
If immunotherapy is administered without methylation monitoring, then treatment protocol is simplified, but treatment effectiveness is reduced
Solution Approach 1:
The patent implements a feedback mechanism where methylation status检测结果 feeds into treatment decision-making. Based on the detected methylation state of the STING promoter, the system adjusts immunotherapy administration accordingly - proceeding with immunotherapy when methylation indicates potential responsiveness, and modifying or delaying treatment when methylation suggests resistance, thereby optimizing treatment effectiveness
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for personalized treatment decisions based on STING promoter methylation status, potentially transforming immunologically 'cold' tumors into 'hot' ones, enhancing immune responses and improving cancer treatment efficacy.
Implementation Method 1
administration of demethylating agents like azacitidine or decitabine to restore STING expression and function
Data Source
AI summary
The present disclosure describes methylation markers in the STING promoter useful for making treatment decisions regarding certain cancer and tumors, such as cranial cancers or extracranial cancers of neuroectodermal embryologic origin. The present disclosure also describes methylation markers in the STING promoter for making treatment decisions regarding brain malignancies. These methylation markers serve as indicators of the likelihood of the tumor or cancer being responsive to certain therapeutic modalities, such as an immunotherapy. The present disclosure also describes methods of decreasing the methylation state of the STING promoter in a patient via the administration of a demethylating agent to improve outcomes and increase the likelihood of responding positively to therapies.